Co-Diagnostics Raises $2.67M via Warrant Inducement, Issues 3.4M New Warrants at $1.56

summarizeSummary

Co-Diagnostics raised $2.67 million by inducing early exercise of existing warrants, issuing 3.4 million new warrants at $1.56 in return — a lifeline for the cash-strapped diagnostics company, but at the cost of substantial future dilution.

check_boxKey Events · Financing and Capital Events · CODX

• Warrant Inducement Raises $2.67M

  Holders exercised 1,702,362 existing warrants at $1.571 per share, providing approximately $2.67 million in gross proceeds before fees.

• 3.4M New Warrants Issued at $1.56

  As inducement, the company issued 3,404,724 new warrants with a $1.56 exercise price — double the shares exercised — exercisable only after stockholder approval, with a five-year term from approval.

• Potential Dilution of ~49%

  If all new warrants are exercised, outstanding shares would increase by approximately 3.4 million from the post-transaction base of 6.98 million, representing roughly 49% dilution.

• Stockholder Approval Required

  The new warrants cannot be exercised until Nasdaq-compliant stockholder approval is obtained; the company must hold a vote within 90 days and every 90 days thereafter until approval.

auto_awesomeAnalysis · CODX · Industrial Applications And Services

Facing a going-concern warning and a market cap of just $8.2 million, Co-Diagnostics persuaded holders of 1.7 million existing warrants to exercise early at $1.571, injecting $2.67 million in cash. In return, the company issued 3.4 million new warrants with a $1.56 strike — double the shares, at a slightly lower price. These new warrants cannot be exercised until shareholders approve, creating a near-term overhang. The cash buys time, but the potential dilution is significant: if all new warrants are exercised, outstanding shares would rise by roughly 49% from the post-transaction base of 6.98 million shares.